GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Clinical trial NCT05130255 · TERMINATED

Trial details

NCT number: NCT05130255
Sponsor: Y-mAbs Therapeutics
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

SCLC Malignant Melanoma Sarcoma High Risk Neuroblastoma

Start date: 2022-11-17
Primary completion: 2026-03-11
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.